MIRM - NASDAQ
Mirum Pharmaceuticals, Inc.
$91.83
-0.016%Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
At a Glance
Live SnapshotMirum Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Mirum Pharmaceuticals, Inc. Cash Flow Statement
MIRM • NASDAQ
| Mirum Pharmaceuticals, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-23.4M | -87.9M | -163.4M | -135.7M | -84M | -103.3M | -52.6M | -17.3M | |
24.2M | 23.6M | 10.8M | 3.7M | 975K | 623K | 324K | 0.0 | |
0.0 | 0.0 | 0.0 | -6.6M | 595K | 72K | 0.0 | 0.0 | |
71.4M | 48.4M | 35M | 27M | 23.1M | 12.6M | 6.1M | 51K | |
3.2M | 3.6M | 69.3M | 12.5M | -90.4M | 335K | -326K | 12.1M | |
(0.0) | (1M) | (125K) | (0.0) | (0.0) | (11K) | (21K) | (0.0) | |
-19.7M | 22.6M | -22.6M | -21.1M | 17M | 611K | 7.1M | 2.4M | |
55.8M | 10.3M | -70.9M | -120.1M | -132.8M | -89.1M | -39.4M | -373K | |
INVESTING ACTIVITIES | ||||||||
-954K | -993K | -109K | -278K | -19M | -225K | -281K | -7.5M | |
(0.0) | (0.0) | -212.8M | -8M | -19M | -38.1M | (127.5M) | (0.0) | |
-97.4M | -89M | -27.3M | -132.3M | -198M | -74.6M | -152M | (0.0) | |
74.4M | 19.9M | 153M | 140.3M | 157.6M | 112.7M | 24.5M | 0.0 | |
0.0 | -20M | -20M | 8M | 127M | 38.1M | -127.5M | -11.3M | |
-24M | -90.1M | -107.2M | (7.7M) | (48.5M) | (37.9M) | -127.8M | -7.5M | |
FINANCING ACTIVITIES | ||||||||
40.1M | 17.7M | 216.7M | 107.4M | 6.9M | 131.9M | 67.2M | 59.8M | |
0.0 | 0.0 | 305.3M | 0.0 | 0.0 | 0.0 | 0.0 | 50K | |
0.0 | 0.0 | -185.4M | 1.7M | 66.6M | 49.4M | 0.0 | 0.0 | |
40.1M | 17.7M | 336.6M | 109.1M | 73.5M | 181.3M | 127.2M | 59.8M | |
CASH FLOW SUMMARY | ||||||||
3.2M | -1.3M | -133K | 12K | -1K | 29K | -27K | 0.0 | |
75.2M | -63.4M | 158.3M | -3.3M | -10.7M | 130.1M | -40M | 52M | |
222.9M | 286.3M | 128M | 131.3M | 142.1M | 12M | 52M | 0.0 | |
298.2M | 222.9M | 286.3M | 128M | 131.3M | 142.1M | 12M | 52M | |
54.9M | 9.3M | -91.1M | -120.4M | -151.8M | -89.3M | -39.6M | -7.9M |
SEC Filings
MIRM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
8-K/A 8-K/A 2026 (Amended) N/A | April 08, 2026 | January 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 26, 2026 | January 23, 2026 | 2026 |
Related Guides
Continue your MIRM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.